| pubmed-article:20347281 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:20347281 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:20347281 | lifeskim:mentions | umls-concept:C0006826 | lld:lifeskim |
| pubmed-article:20347281 | lifeskim:mentions | umls-concept:C0039593 | lld:lifeskim |
| pubmed-article:20347281 | lifeskim:mentions | umls-concept:C0728747 | lld:lifeskim |
| pubmed-article:20347281 | lifeskim:mentions | umls-concept:C1552617 | lld:lifeskim |
| pubmed-article:20347281 | lifeskim:mentions | umls-concept:C1522326 | lld:lifeskim |
| pubmed-article:20347281 | lifeskim:mentions | umls-concept:C0282443 | lld:lifeskim |
| pubmed-article:20347281 | lifeskim:mentions | umls-concept:C1524063 | lld:lifeskim |
| pubmed-article:20347281 | lifeskim:mentions | umls-concept:C1522673 | lld:lifeskim |
| pubmed-article:20347281 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:20347281 | pubmed:dateCreated | 2010-4-19 | lld:pubmed |
| pubmed-article:20347281 | pubmed:abstractText | This review of practice assessed all early breast cancer patients diagnosed over 12 months to determine the frequency of human epidermal growth factor receptor 2 (HER2) positivity and trastuzumab use. The frequency of HER2 positivity in routine practice (185/1319; 14%) was less than expected. A significant proportion of patients (56/185; 30%) did not receive trastuzumab, largely due to concerns about chemotherapy tolerability. | lld:pubmed |
| pubmed-article:20347281 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20347281 | pubmed:language | eng | lld:pubmed |
| pubmed-article:20347281 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20347281 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:20347281 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20347281 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20347281 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20347281 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20347281 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20347281 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:20347281 | pubmed:month | May | lld:pubmed |
| pubmed-article:20347281 | pubmed:issn | 1433-2981 | lld:pubmed |
| pubmed-article:20347281 | pubmed:author | pubmed-author:ColemanR ERE | lld:pubmed |
| pubmed-article:20347281 | pubmed:author | pubmed-author:RamakrishnanS... | lld:pubmed |
| pubmed-article:20347281 | pubmed:author | pubmed-author:PurohitO POP | lld:pubmed |
| pubmed-article:20347281 | pubmed:author | pubmed-author:KumarV SVS | lld:pubmed |
| pubmed-article:20347281 | pubmed:author | pubmed-author:HattonM QMQ | lld:pubmed |
| pubmed-article:20347281 | pubmed:author | pubmed-author:DunnK SKS | lld:pubmed |
| pubmed-article:20347281 | pubmed:author | pubmed-author:CoulsonS GSG | lld:pubmed |
| pubmed-article:20347281 | pubmed:author | pubmed-author:ManifoldI MIM | lld:pubmed |
| pubmed-article:20347281 | pubmed:author | pubmed-author:BridgewaterCC | lld:pubmed |
| pubmed-article:20347281 | pubmed:copyrightInfo | Copyright 2010 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved. | lld:pubmed |
| pubmed-article:20347281 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:20347281 | pubmed:volume | 22 | lld:pubmed |
| pubmed-article:20347281 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:20347281 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:20347281 | pubmed:pagination | 289-93 | lld:pubmed |
| pubmed-article:20347281 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:20347281 | pubmed:meshHeading | pubmed-meshheading:20347281... | lld:pubmed |
| pubmed-article:20347281 | pubmed:meshHeading | pubmed-meshheading:20347281... | lld:pubmed |
| pubmed-article:20347281 | pubmed:meshHeading | pubmed-meshheading:20347281... | lld:pubmed |
| pubmed-article:20347281 | pubmed:meshHeading | pubmed-meshheading:20347281... | lld:pubmed |
| pubmed-article:20347281 | pubmed:meshHeading | pubmed-meshheading:20347281... | lld:pubmed |
| pubmed-article:20347281 | pubmed:meshHeading | pubmed-meshheading:20347281... | lld:pubmed |
| pubmed-article:20347281 | pubmed:meshHeading | pubmed-meshheading:20347281... | lld:pubmed |
| pubmed-article:20347281 | pubmed:meshHeading | pubmed-meshheading:20347281... | lld:pubmed |
| pubmed-article:20347281 | pubmed:year | 2010 | lld:pubmed |
| pubmed-article:20347281 | pubmed:articleTitle | Review of testing and use of adjuvant trastuzumab across a cancer network--are we treating the right patients? | lld:pubmed |
| pubmed-article:20347281 | pubmed:affiliation | Academic Unit of Clinical Oncology, Weston Park Hospital, Sheffield, UK. | lld:pubmed |
| pubmed-article:20347281 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:20347281 | pubmed:publicationType | Review | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:20347281 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:20347281 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:20347281 | lld:pubmed |
